Finance & Corporate

Mediolanum Farmaceutici acquires the French company ElsaLys Biotech to develop next generation immuno-oncology therapies

Thu, 05/07/2020 - 10:30

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its

ElsaLys Biotech at BIO-Europe 2018

Mon - 07, 11/05 - 07/2018 - 09:00

Do not hesitate to contact us if you want to meet our team during Bio-Eu

ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH® MARKET

Fri, 04/20/2018 - 08:30

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

ELSALYS BIOTECH announces the completion of the first instalment of a total fundraising amounting to € 5 million

Tue, 11/03/2015 - 17:00

IM Europe and Sofimac Partners are the main investors

ELSALYS BIOTECH expands its team to strengthen its strategy and the development of its programs

Mon, 01/30/2017 - 17:00

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

Tue, 07/18/2017 - 17:00

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®, an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

Thu, 10/12/2017 - 17:00

In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC®

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Subscribe now

Contactez Nous

Headquarters, R&D, Shipping Address : ElsaLys Biotech SA, 317 Avenue Jean Jaurès, 69007 Lyon, France LYON: +33 (0)4 37 28 73 00

Administrative site : Centre d’affaires Athena pour ElsaLys Biotech, 2 rue Henri Bergson – CS 90026 F-67087 Strasbourg, France STRASBOURG: +33 (0)3 88 29 03 00

contact@elsalysbiotech.com

Finance & Corporate

Catégories d'actualités

Mediolanum Farmaceutici acquires the French company ElsaLys Biotech to develop next generation immuno-oncology therapies

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its

ElsaLys Biotech at BIO-Europe 2018

ELSALYS BIOTECH ANNOUNCES THE REGISTRATION OF ITS DOCUMENT DE BASE IN THE CONTEXT OF ITS PROPOSED INITIAL PUBLIC OFFERING ON THE PARIS EURONEXT GROWTH® MARKET

Not to be distributed directly or indirectly in the United States, Canada, Australia or Japan

ELSALYS BIOTECH announces the completion of the first instalment of a total fundraising amounting to € 5 million

IM Europe and Sofimac Partners are the main investors

ELSALYS BIOTECH expands its team to strengthen its strategy and the development of its programs

After having recently enriched its pipeline of therapeutic antibodies in oncology, ElsaLys Biotech strengthens its management team with the arriva

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®, an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC®

Contactez Nous